Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Moodys
McKesson
Boehringer Ingelheim

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR REVEFENACIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Revefenacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01704404 ↗ 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease Completed Theravance Biopharma Phase 2 2012-12-01 This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
NCT01704404 ↗ 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease Completed Mylan Inc. Phase 2 2012-12-01 This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
NCT01704404 ↗ 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease Completed Theravance Biopharma R & D, Inc. Phase 2 2012-12-01 This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
NCT02040792 ↗ A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma Phase 2 2014-05-01 This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
NCT02040792 ↗ A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Completed Mylan Inc. Phase 2 2014-05-01 This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Revefenacin

Condition Name

Condition Name for Revefenacin
Intervention Trials
Chronic Obstructive Pulmonary Disease (COPD) 5
COPD 5
Chronic Obstructive Pulmonary Disease 2
Chronic Obstructive Pulmonary Disease, COPD 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Revefenacin
Intervention Trials
Lung Diseases, Obstructive 12
Pulmonary Disease, Chronic Obstructive 12
Lung Diseases 11
Respiratory Aspiration 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Revefenacin

Trials by Country

Trials by Country for Revefenacin
Location Trials
United States 32
New Zealand 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Revefenacin
Location Trials
South Carolina 6
Florida 4
Oregon 3
North Carolina 3
Tennessee 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Revefenacin

Clinical Trial Phase

Clinical Trial Phase for Revefenacin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Revefenacin
Clinical Trial Phase Trials
Completed 14
Not yet recruiting 2
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Revefenacin

Sponsor Name

Sponsor Name for Revefenacin
Sponsor Trials
Mylan Inc. 17
Theravance Biopharma 16
Theravance Biopharma R & D, Inc. 12
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Revefenacin
Sponsor Trials
Industry 48
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
McKinsey
Johnson and Johnson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.